Improvement of dermatological symptoms in patients with Bachmann-Bupp syndrome using difluoromethylornithine treatment

Pediatr Dermatol. 2023 May-Jun;40(3):528-531. doi: 10.1111/pde.15187. Epub 2022 Nov 28.

Abstract

Bachmann-Bupp syndrome (OMIM #619075) is a novel autosomal dominant disorder caused by variants in the c-terminus of the ornithine decarboxylase 1 gene, resulting in increased levels of ornithine decarboxylase. This case report includes two patients diagnosed with Bachmann-Bupp syndrome who were treated with difluoromethylornithine through compassionate use approval from the United States Food and Drug Administration. In both patients, treatment with difluoromethylornithine has resulted in improved dermatologic signs, including regrowth of eyebrow and scalp hair and cessation of recurrent follicular cyst development.

Keywords: alopecia; difluoromethylornithine; drug therapy; follicular cyst; ornithine decarboxylase.

Publication types

  • Case Reports

MeSH terms

  • Eflornithine* / therapeutic use
  • Humans
  • Ornithine
  • Ornithine Decarboxylase Inhibitors
  • Ornithine Decarboxylase* / genetics
  • United States

Substances

  • Eflornithine
  • Ornithine Decarboxylase
  • Ornithine Decarboxylase Inhibitors
  • Ornithine